Your browser doesn't support javascript.
loading
Non-selective ß-blockers are associated with improved survival in patients with ascites listed for liver transplantation.
Leithead, Joanna A; Rajoriya, Neil; Tehami, Nadeem; Hodson, James; Gunson, Bridget K; Tripathi, Dhiraj; Ferguson, James W.
Afiliación
  • Leithead JA; Liver Unit, Queen Elizabeth Hospital, Birmingham, UK NIHR Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham, UK.
  • Rajoriya N; Liver Unit, Queen Elizabeth Hospital, Birmingham, UK.
  • Tehami N; Liver Unit, Queen Elizabeth Hospital, Birmingham, UK.
  • Hodson J; Department of Statistics, Wolfson Building, Queen Elizabeth Hospital, Birmingham, UK.
  • Gunson BK; Liver Unit, Queen Elizabeth Hospital, Birmingham, UK NIHR Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham, UK.
  • Tripathi D; Liver Unit, Queen Elizabeth Hospital, Birmingham, UK.
  • Ferguson JW; Liver Unit, Queen Elizabeth Hospital, Birmingham, UK.
Gut ; 64(7): 1111-9, 2015 Jul.
Article en En | MEDLINE | ID: mdl-25281417
OBJECTIVE: Recent data have suggested that non-selective ß-blockers (NSBB) are associated with increased mortality in patients with cirrhosis and refractory ascites. However, other evidence implies that NSBB may be beneficial in this setting by reducing bacterial translocation. Our aim was to determine whether NSBB use was a risk factor for mortality in patients with end-stage chronic liver disease and ascites awaiting liver transplantation. DESIGN: This was a single-centre retrospective study of 322 patients with ascites listed January 2007 to July 2011. RESULTS: NSBB patients (n=159) and non-NSBB patients (n=163) were comparable with regards to listing model for end-stage liver disease score (p=0.168), frequency of hepatocellular carcinoma (p=0.193) and refractory ascites (35.2% vs. 37.4%, p=0.681). 82 patients died, 221 patients were transplanted and 19 patients were removed from the list during a median follow-up duration of 72 days; the median time to death was 150 and 54 days in the NSBB and non-NSBB groups, respectively. In a multivariate competing risk Cox model, patients on NSBB had reduced mortality compared with propensity risk score-matched non-NSBB patients (HR 0.55; 95% CI 0.32 to 0.95, p=0.032). Similarly, in the subgroup of patients with refractory ascites (n=117), NSBB remained independently associated with less waitlist death (adjusted HR 0.35; 95% CI 0.14 to 0.86, p=0.022). CONCLUSIONS: NSBB in patients with ascites and refractory ascites listed for liver transplantation are not detrimental, and instead are associated with reduced waitlist death. Our findings argue that NSBB are safe and may confer benefit in patients with ascites complicating end-stage liver disease.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ascitis / Enfermedad Hepática en Estado Terminal Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Gut Año: 2015 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ascitis / Enfermedad Hepática en Estado Terminal Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Gut Año: 2015 Tipo del documento: Article Pais de publicación: Reino Unido